DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Pujade-Lauraine E, Ledermann JA, Selle F. et al.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol 2017;
18: 1274-1284
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.